Related Experiment Video
Updated: Jul 11, 2026

Studies on the Anti-Inflammatory Effect of Xiaoyao Pills in The Treatment of Postmenopausal Osteoporosis in Mice
Published on: August 23, 2024
Osteoporosis: non-hormonal treatment
1Division of Bone Diseases (World Health Organization Collaborating Center for Osteoporosis Prevention), Department of Rehabilitation and Geriatrics, University Hospitals, Geneva, Switzerland.
Osteoporosis treatments like bisphosphonates, hormone therapy, and denosumab effectively reduce fracture risks. Calcium and vitamin D also help prevent falls and hip fractures, especially in older adults.
Area of Science:
- Bone biology and pharmacology
- Geriatric medicine
- Endocrinology
Background:
- Osteoporosis treatment has advanced with new drugs and administration schedules.
- Long-term safety data for osteoporosis therapies are increasingly available.
Purpose of the Study:
- To review current osteoporosis treatments and their efficacy in reducing fracture risk.
- To highlight novel agents and their impact on bone mineral density.
Main Methods:
- Review of clinical trials and meta-analyses on osteoporosis medications.
- Analysis of fracture risk reduction data for various agents.
- Comparison of bone mineral density changes with different treatments.
Main Results:
- Alendronate, risedronate, strontium ranelate, and zoledronate reduce vertebral and hip fracture risks.
- Calcium and vitamin D supplementation decreases fall and hip fracture risk in institutionalized patients.
- Denosumab demonstrates potent bone resorption inhibition and increases bone mineral density.
Conclusions:
- Multiple pharmacologic agents effectively reduce fracture risk in osteoporosis.
- Newer agents like denosumab show promising results in improving bone density.
- Combination therapy with parathyroid hormone and bone resorption inhibitors does not appear to offer additional benefits.
Related Concept Videos
Bone Remodeling
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Osteoclasts in Bone Remodeling